Veeva Systems (NYSE:VEEV) Releases Q3 2027 Earnings Guidance

Veeva Systems (NYSE:VEEV) updated its third quarter 2027 earnings guidance on Wednesday. The company provided EPS guidance of 2.330-2.340 for the period, compared to the consensus earnings per share estimate of 2.160. The company issued revenue guidance of $932.0 million-$935.0 million, compared to the consensus revenue estimate of $917.9 million. Veeva Systems also updated its FY 2027 guidance to 9.210-9.210 EPS.

Veeva Systems Stock Down 0.8%

Shares of VEEV traded down $2.06 during trading hours on Wednesday, reaching $244.72. 1,432,545 shares of the company traded hands, compared to its average volume of 2,452,867. The stock has a market capitalization of $39.75 billion, a PE ratio of 43.62, a price-to-earnings-growth ratio of 1.07 and a beta of 0.92. The stock has a fifty day simple moving average of $201.60 and a 200 day simple moving average of $182.61. Veeva Systems has a fifty-two week low of $148.05 and a fifty-two week high of $310.50.

Veeva Systems (NYSE:VEEV) last released its earnings results on Wednesday, June 3rd. The technology company reported $2.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. Veeva Systems had a net margin of 28.37% and a return on equity of 13.72%. The company had revenue of $882.95 million for the quarter, compared to analyst estimates of $857.73 million. During the same period in the prior year, the firm earned $1.97 EPS. The firm’s quarterly revenue was up 16.3% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. Research analysts predict that Veeva Systems will post 6.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VEEV has been the subject of several recent research reports. BMO Capital Markets lowered their price target on Veeva Systems from $220.00 to $175.00 and set a “market perform” rating for the company in a report on Thursday, June 4th. Wall Street Zen cut Veeva Systems from a “buy” rating to a “hold” rating in a research note on Monday, August 3rd. Robert W. Baird upped their target price on Veeva Systems from $250.00 to $260.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Guggenheim upped their target price on shares of Veeva Systems from $232.00 to $276.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Finally, Zacks Research lowered shares of Veeva Systems from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Nineteen investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $258.08.

Insider Activity

In related news, insider Thomas D. Schwenger sold 36,000 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $250.23, for a total value of $9,008,280.00. Following the sale, the insider directly owned 19,449 shares of the company’s stock, valued at $4,866,723.27. This represents a 64.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.60% of the company’s stock.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Major customer wins strengthen Vault CRM adoption. Biogen and Regeneron both committed to Veeva Vault CRM globally. The agreements support Veeva’s position in life-sciences commercial software and could contribute to future subscription growth. Veeva Vault CRM Selected by Biogen Veeva Vault CRM Selected by Regeneron
• Positive Sentiment: Truist said the wins reinforce Veeva’s market leadership. The bank characterized Vault CRM as the clear leader in life-sciences CRM ahead of earnings, providing a favorable read-through on competitive positioning and demand. Veeva’s Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings
• Positive Sentiment: Needham reaffirmed its “Buy” rating. The repeated bullish recommendation adds support to the investment case as investors assess Veeva’s growth prospects and valuation. Needham Reaffirms Buy Rating
• Neutral Sentiment: Piper Sandler initiated coverage. New analyst coverage may increase institutional attention, although the article does not specify the firm’s rating or price target. Veeva Coverage Initiated at Piper Sandler
• Neutral Sentiment: Earnings remain the near-term catalyst. Veeva is scheduled to report second-quarter results after the bell. Its previous quarter exceeded consensus estimates, with revenue up 16.3% year over year, so investors will focus on results, subscription growth, and forward guidance. What to Expect From Veeva Systems’s Q2 Earnings

Institutional Trading of Veeva Systems

A number of institutional investors and hedge funds have recently modified their holdings of VEEV. Invesco Ltd. lifted its holdings in shares of Veeva Systems by 12.5% in the 4th quarter. Invesco Ltd. now owns 323,302 shares of the technology company’s stock worth $72,171,000 after purchasing an additional 35,832 shares during the last quarter. Corient Private Wealth LLC boosted its stake in Veeva Systems by 33.4% during the 4th quarter. Corient Private Wealth LLC now owns 196,746 shares of the technology company’s stock valued at $43,920,000 after purchasing an additional 49,279 shares during the period. EP Wealth Advisors LLC acquired a new position in Veeva Systems during the 4th quarter valued at about $942,000. Coastal Bridge Advisors LLC grew its position in Veeva Systems by 47.3% in the 4th quarter. Coastal Bridge Advisors LLC now owns 1,022 shares of the technology company’s stock worth $228,000 after purchasing an additional 328 shares during the last quarter. Finally, Cim LLC raised its holdings in shares of Veeva Systems by 2.6% during the fourth quarter. Cim LLC now owns 5,712 shares of the technology company’s stock valued at $1,275,000 after buying an additional 146 shares during the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.